透云生物(01332) - 2024 - 年度业绩

Announcement Overview This announcement provides a quarterly update on the action plan to address audit qualifications and ensures compliance with listing rules Purpose and Background of Announcement This announcement supplements the 2024 annual report, updating on the audit qualification action plan and board compliance with listing rules - This announcement supplements the 2024 annual report, primarily providing a quarterly update on the action plan to address audit qualifications[3] - The Board of Directors issues this announcement in compliance with Rule 13.09(2) of the Listing Rules and the Inside Information Provisions of Part XIVA of the SFO[3] Quarterly Update on Mitigation Measures for Audit Qualifications The company is implementing diverse strategies including business expansion, debt management, asset disposal, and market promotion to address audit qualifications Business Expansion and Revenue Streams The company is launching new health products to expand its customer base and revenue streams, capitalizing on market growth potential - The company is launching a series of new health products targeting diverse customer groups to expand its customer base and revenue streams[4] - The Board believes the health product market has significant growth potential due to increasing public health awareness[4] Debt Management and Fundraising The company actively manages debt and raises working capital through shareholder commitments, new loans, and loan term extensions - Director Mr. Wang Liang and Shareholder Ms. Qiao Yanfeng have committed not to demand repayment of approximately HK$121.8 million in outstanding debts until the Group has sufficient cash reserves[4] New Loan Details | Source | Amount (HKD) | Purpose | | :--- | :--- | :--- | | Mr. Wang Liang | 2.3 million | Working Capital | | Several Borrowers | 28.0 million | Working Capital | - The company is negotiating with a borrower to extend the term of a loan with a principal amount of RMB60 million due on June 7, 2025, with the borrower indicating willingness to negotiate and not pursue collection actions[4] Asset Disposal and Efficiency Improvement The company is increasing working capital by divesting non-core assets and unprofitable businesses, having completed two subsidiary equity sales with significant expected gains - The company is exploring increasing working capital by realizing non-core asset projects and divesting unprofitable businesses[4] Subsidiary Equity Disposal Details | Disposal Date | Percentage of Shares Disposed | Consideration (RMB) | Estimated Unaudited Disposal Gain (HKD) | | :--- | :--- | :--- | :--- | | March 6, 2025 | 30% | 5,000,000 | 6,000,000 | | May 6, 2025 | 70% | 13,000,000 | 15,300,000 | Market Promotion and Distribution Strategy The company is accelerating product distribution and customer engagement through negotiations with supermarket chains and collaborations with key opinion leaders for live stream promotions - The company is in ongoing discussions with leading supermarket chains/groups regarding formal agreements for the distribution and sale of the Group's products[5] - The company is collaborating with several renowned Key Opinion Leaders to promote products and boost sales through live streaming commerce channels[5] Other Important Information The company advises caution for investors and provides the current composition of its Board of Directors Investment Advisory and Board Composition The company advises shareholders and potential investors to exercise caution when trading its securities and lists the current Board of Directors - The company reminds shareholders and potential investors to exercise caution when dealing in the company's securities[6] - As of the announcement date, the Board of Directors comprises Mr. Wang Liang (Chairman), Mr. Du Dong (Executive Director), Mr. Chen Hui, Ms. Tian Yuze, Mr. Zhang Lele (Non-executive Directors), and Mr. Zhang Rongping, Mr. Xia Qicai, Mr. Du Chengquan (Independent Non-executive Directors)[6]